Incomplete surgery · adults and children with chronic rhinosinusitis with or without nasal polyps
Tranexamic acid showed no clear difference in incomplete surgery compared with placebo (saline solution or sterile water) (moderate certainty).
1 finding from 1 review
Overall rate of surgical complications · adults and children with chronic rhinosinusitis with or without nasal polyps
Tranexamic acid showed no clear difference in surgical complications compared with placebo (saline solution or sterile water) (moderate certainty).
1 finding from 1 review
Postoperative bleeding (place of packing or revision surgery within 14 days of surgery) · adults and children with chronic rhinosinusitis with or without nasal polyps
Tranexamic acid showed no clear difference in postoperative bleeding (place of packing or revision surgery within… compared with placebo (saline solution or sterile water) (low certainty).
1 finding from 1 review
Improvement in symptoms at ≤ 3 months · carpal tunnel syndrome
1 finding from 1 review
Improvement in function at ≤ 3 months · carpal tunnel syndrome
1 finding from 1 review
Improvement in symptoms at > 3 months · carpal tunnel syndrome
1 finding from 1 review
Improvement in neurophysiological parameters at ≤ 3 months · carpal tunnel syndrome
1 finding from 1 review
Requirement for carpal tunnel surgery · carpal tunnel syndrome
Local corticosteroid injection (LCI) probably leads to lower requirement for carpal tunnel surgery compared with saline no treatment or placebo (moderate certainty).
1 finding from 1 review
Improvement in quality of life · carpal tunnel syndrome
1 finding from 1 review
Adverse events · carpal tunnel syndrome
1 finding from 1 review
All‐cause mortality at day 28 · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in all‐cause mortality at day 28 compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.79 [0.43, 1.44]
Studies not reported
Low
Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in improvement of clinical status (number of participants discharged… compared with saline placebo (low certainty).
1 finding from 1 review
Quality of life · individuals with moderate or severe COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.
1 finding from 1 review
OR 4
3 participants
GRADE not reported
Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Worsening of clinical status at day 28 (data only available for clinical status worsened on day 7) · individuals with moderate or severe COVID‐19
It is very uncertain whether hyperimmune immunoglobulin from human plasma changes worsening of clinical status at day 28 (data only available for… compared with saline placebo (very low certainty).
1 finding from 1 review
RR 0.85 [0.58, 1.23]
Studies not reported
Very low
Improvement of clinical status · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in improvement of clinical status (number of people discharged from… compared with saline placebo (moderate certainty).
1 finding from 1 review
RR 1.02 [0.97, 1.08]
Studies not reported
Moderate
Quality of life · individuals with moderate or severe COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in adverse events of any grade up to 28 days (data only available for… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.98 [0.81, 1.18]
Studies not reported
Low